QuatRx Pharmaceuticals

Developing therapeutics for under-served endocrine and metabolic diseases

QuatRx is focused on development of therapeutics for endocrine and metabolic diseases. The company's lead product Osphena, a selective estrogen receptor modulator, was approved by the FDA in 2013 to treat dyspareunia. Q

Status

Acquired by Shionogi in 2017

Year of Investment

2000

Strategy

Life Sciences

Subsector

Development-Stage Therapeutics

Location

Ann Arbor, Michigan

Frazier Team